RHYTHM Biosciences Ltd Market Cap ($14.62 Million)
Market Cap & Net Worth: RHYTHM Biosciences Ltd (RHY)
RHYTHM Biosciences Ltd market cap. RHYTHM Biosciences Ltd (AU:RHY) has a market capitalization of $14.62 Million (AU$20.66 Million) as of November 1, 2026. Listed on the AU stock exchange, this Australia-based company holds position #25937 globally and #1135 in its home market, demonstrating a -5.97% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RHYTHM Biosciences Ltd's stock price AU$0.06 by its total outstanding shares 327979001 (327.98 Million). Also see how efficiently does RHYTHM Biosciences Ltd generate cash for how efficiently the company converts equity into cash flow.
RHYTHM Biosciences Ltd Market Cap History (2017–2026)
RHYTHM Biosciences Ltd market cap history from 2017 to 2026. Data shows change from $64.98 Million to $14.62 Million (-16.83% CAGR). Check RHY stock price and chart for real-time trading data and today's change.
RHYTHM Biosciences Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RHYTHM Biosciences Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of RHYTHM Biosciences Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
9.82x
RHYTHM Biosciences Ltd's market cap is 9.82 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $32.49 Million | $64.48K | -$1.75 Million | 503.87x | N/A |
| 2019 | $30.17 Million | $1.03 Million | -$2.55 Million | 29.35x | N/A |
| 2020 | $203.06 Million | $100.00K | -$4.02 Million | 2030.58x | N/A |
| 2021 | $359.70 Million | $1.11 Million | -$6.61 Million | 324.35x | N/A |
| 2022 | $229.75 Million | $2.43 Million | -$8.79 Million | 94.66x | N/A |
| 2023 | $31.33 Million | $3.10 Million | -$8.22 Million | 10.12x | N/A |
| 2024 | $20.19 Million | $1.69 Million | -$6.86 Million | 11.95x | N/A |
| 2025 | $31.33 Million | $3.19 Million | -$3.83 Million | 9.82x | N/A |
Competitor Companies of RHY by Market Capitalization
Companies near RHYTHM Biosciences Ltd in the global market cap rankings as of November 1, 2026. Also see RHY current and non-current assets for a full breakdown of the balance sheet.
Key companies related to RHYTHM Biosciences Ltd by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #143 globally with a market cap of $164.04 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #530 globally with a market cap of $51.40 Billion USD ( CN¥351.23 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $697.00 |
| #143 | Danaher Corporation | NYSE:DHR | $164.04 Billion | $232.23 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $414.30 |
| #530 | WuXi AppTec Co Ltd | SHG:603259 | $51.40 Billion | CN¥142.01 |
Market Capitalization of RHYTHM Biosciences Ltd (2017–2026)
Market capitalization of RHYTHM Biosciences Ltd from 2017 to today. Between 2017 and today, RHYTHM Biosciences Ltd's market cap moved from $64.98 Million to $ 14.62 Million, with a yearly change of -16.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$14.62 Million | -53.33% |
| 2025 | AU$31.33 Million | +55.17% |
| 2024 | AU$20.19 Million | -35.56% |
| 2023 | AU$31.33 Million | -86.36% |
| 2022 | AU$229.75 Million | -36.13% |
| 2021 | AU$359.70 Million | +77.14% |
| 2020 | AU$203.06 Million | +573.08% |
| 2019 | AU$30.17 Million | -7.14% |
| 2018 | AU$32.49 Million | -50.00% |
| 2017 | AU$64.98 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of RHYTHM Biosciences Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.62 Million USD |
| MoneyControl | $14.62 Million USD |
| MarketWatch | $14.62 Million USD |
| marketcap.company | $14.62 Million USD |
| Reuters | $14.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About RHYTHM Biosciences Ltd
Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more